Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (340)	2/2/1999 8:31:00 AM
From: WWS	Respond to of 613

Here's a link to Richard H's take on the situation:' exchange2000.com

To: Arthur Radley who wrote (340)	2/2/1999 9:07:00 AM
From: LLCF	Read Replies (1) \| Respond to of 613

CLPA is trading 9 1/2-10 this early this morning... wow what a whack. It made front page WSJ. Article on page B2 of the WSJ this morning about how Venture Capital firms are buying shares in public biotech companies... 2 edged sword... startups are having a hard time with the public companies so cheap. "New Enterprise Associates" (Menlo Park) is mentioned as finding "diamonds in the rough". DAK

To: Arthur Radley who wrote (340)	2/2/1999 10:35:00 AM
From: LLCF	Read Replies (2) \| Respond to of 613

Another disaster du jour: NRGN... American Home has dropped dvelopment of their epilepsy product after finding adverse side effects. Stock is down 5 1/4 to $12 on the day. All the usual suspects on CNBC crowing about how risky these small companies. DAK

To: Arthur Radley who wrote (340)	2/2/1999 1:37:00 PM
From: RCMac	Read Replies (2) \| Respond to of 613

Just after I posted the link to a list of SI's most bookmarked people the other day, SI published the more recent quarterly list: Message 7578568 As before, Rick Harmon is the only biotech investor on the list, although with 300 bookmarks he has climbed to about 31st on the list. Amazing to me that biotech contributors of the quality and generosity (and profitability) of PeterSuzman, Vector1, Rocketman, Miljenko Zuanic, James Silverman (see, e.g., Message 5602511 and Message 4988589 ), John Metcalf, Larry Liebman, margie, etc. have gone largely unnoticed. Jim Silverman has gone a bit quiet, and margie has posted mostly on AGPH, so I guess their obscurity is understandable, but it's just bonkers as to the others. Note also the 100 most bookmarked subjects: Message 7578738 --mostly computer/communications technology and trading/"momentum investing" threads; not a single biotech thread on the list (although a few biotech stocks get mentioned, briefly and transiently, on some of the traders' and overvalued stocks threads). Biotech remains a rarified taste, probably to our longer-term advantage as investors (some of these things are surely incredibly cheap as we wait for the science to mature and result in products - all very appealing to the value investor instincts that keep me away from anything but CSCO in the internet line) but to the appalling disadvantage of good companies with good science of tremendous use to the community at large. And today's disasters and CNBC's natterings about risky little biotech companies, as TD and DAK note, will hardly help. --RCM